Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide) are highly effective pharmacologic interventions for obesity, producing significant weight loss and metabolic improvements, but their rapid expansion raises safety concerns regarding gastrointestinal side effects, rare serious adverse events, and long-term outcomes not captured in clinical trials.
GLP-1 medications like semaglutide and tirzepatide are currently the most effective non-surgical treatments for obesity, offering weight loss comparable to surgery for many. However, they are not without risks, including common gastrointestinal issues and rare serious side effects. It is crucial to use these medications under strict medical supervision, especially if you have other health conditions, to manage side effects and monitor for long-term safety.
GLP-1-based medications, such as semaglutide and tirzepatide, have transformed obesity care... emerged as the most effective pharmacologic interventions for obesity treatment... Yet the rapid expansion of use... raises important questions regarding safety.
Why this rating
Based on phase 3 trials and widespread clinical adoption, though long-term real-world data is still emerging.
Source
Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety
Ariana M. Chao et al. · PLoS Medicine · 2026
DOI 10.1371/journal.pmed.1004871
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →